Epidemiological Characteristics from a Single Centre Database. Cohort of 1301 Neuroendocrine Tumor Patients: Is There an Association Between Age and Grade of NET? Abstract #1242

Introduction: There is limited data related to epidemiology of NETs and patient survival. For many cancers younger age of diagnosis can be associated with worse survival.
Aim(s): To provide a breakdown of the different characteristics of NET presenting to a tertiary referral centre and examine the association between age of diagnosis and survival.
Materials and methods: Retrospective analysis of 1301 NETs from the database (2000-2013). Demographic data, primary site, grade and age at diagnosis were collected. Survival data was calculated from date of diagnosis to date of death in 166 cases.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Mehmet Yalchin
Keywords: Survival

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment
#872 Urinary 5-hydroxyindoleacetic Acid In Serotonin-Producing Neuroendocrine Tumors: Correlation with Disease Features and Patients' Survival
Introduction: Urinary 5-hydroxyindoleacetic acid (U-5HIAA) is a useful marker for serotonin-producing neuroendocrine tumors (NETs). Its prognostic role, however, is yet to be fully elucidated.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Theo K Bartholomew
#1713 Predictive Factors for Survival in Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) comprise a heterogeneous group of neoplasms with rising incidence.However,prognosticators at diagnosis(Dx) are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Apostolos Koffas
#1126 Long-Term Follow-Up and Survival Data in Progressing Advanced Midgut Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment option for advanced Neuroendocrine Tumours (NET), however long term survival data is lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT, PFS, OS
#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team